Source comparison
Retatrutide Versus Other Weight Loss Medications
Semaglutide (Ozempic/Wegovy) targets only GLP-1 receptors and produces average weight loss around 15%. It has the longest safety track record (approved 2017) and is widely available. For those concerned about newer medications, semaglutide offers a proven opti
This comparison does not assign a generated winner or score.
- Semaglutide (Ozempic/Wegovy) targets only GLP-1 receptors and produces average weight loss around 15%. It has the longest safety track record (approved 2017) and is widely available. For those concerned about newer medications, semaglutide offers a proven option with somewhat less dramatic results.
- Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP receptors, producing approximately 21% average weight loss. It represents the middle ground between single-agonist and triple-agonist approaches. Currently FDA-approved and increasingly available.
- Retatrutide’s triple-agonist approach produces the highest documented weight loss (24.2%) but remains in clinical trials pending FDA approval expected in 2026 or 2027. Those wanting immediate access to FDA-approved options must consider the alternatives, though research peptide versions exist.